From BIO
SBIR Overview and Background Material
BIO Letter to Congress
BIO to Ask Congress to Restore SBIR Grant Eligibility for Small Biotech Companies
Factsheet: Changes in the SBIR Program Threaten Biotechnology Company Funding
From House Hearings 2008
Committee Calls for Sweeping Reforms to SBIR Program
Hearing Testimony, Douglas A. Doerfler, President and Chief Executive Officer, MaxCyte, Inc. on behalf of the Biotechnology Industry Organization (BIO) - “SBIR: America’s National Technology Development Incubator.”
STATEMENT OF ROBERT J. BEALL, Ph.D PRESIDENT AND CEO CYSTIC FIBROSIS FOUNDATION BEFORE THE HOUSE COMMITTEE ON SMALL BUSINESS ON THE SMALL BUSINESS INNOVATION RESEARCH PROGRAM
Testimony of Michael Borrus, Founding General Partner, X/Seed Capital before the U.S. Congress, House of Representatives, Committee on Small Business
House Subcommittee Examines the Role of SBIR in Fostering Medical Breakthroughs
SBIR: Advancing Medical Breakthroughs Statement of Jo Anne Goodnight, SBIR/STTR Program Coordinator, National Institutes of Health, U.S. Department of Health and Human Services
Testimony of the Honorable Amy Comstock Rick, J.D., Chief Executive Officer, Parkinson’s Action Network, Washington, DC, For the U.S. House of Representatives, Committee on Small Business Subcommittee on Investigations and Oversight Hearing on “SBIR: Advancing Medical Breakthroughs”
Hearing Testimony, Melvin Billingsley, Ph.D., President and Chief Executive Officer, Life Sciences Greenhouse of Central Pennsylvania On behalf of Pennsylvania Bio and The Pennsylvania Life Sciences Greenhouse Program
Hearing Testimony F. Nicholas Franano, M.D. Founder and Chief Scientific Officer, Proteon Therapeutics, Inc, Before the House of Representatives on Small Business “SBIR: Advancing Medical Breakthroughs”
STATEMENT BY JAMES STEFANSIC, PHD, MBA, CHIEF TECHNOLOGY OFFICER, PATHFINDER THERAPEUTICS, INC., ON BEHALF OF THE ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (AdvaMed)
NIH website
cartier@bio
nicoleatbio
